Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). Velicept is a portfolio company of NeXeption. For more information, visit www.velicept.com.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/03/15 | $21,000,000 | Series B |
CAM Capital Longitude Capital | undisclosed |
| 10/16/18 | $15,000,000 | Series B Extension |
Becker Ventures CDK Global Fountain Healthcare Partners Longitude Venture Partners Samsara BioCapital  | undisclosed |
